Translational results from the MEDIOLA and TOPACIO phase II trials further demonstrate manageable safety profiles and durable responses with PARP + PD-L1/PD-1 blockade combinations in ovarian, breast, and prostate cancers [101]. Here, PARP1 is linked to prostate carcinoma.